,	OIPE
	SEP 2 2 2004 5
E .	SEP 2 2 2004 (1)
/8	7. 24 5%

Form P10-1449

U.S. Department of Commerce Patent and Trademark Office

ATTY, DOCKET NO. PU60053 SERIAL NO. 10/823,964

Sheet 1 of 3

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APPUCANT Bam, et al.

FIUNG DATE 14 April 2004 GROUP Unknown

(Use several sheets if necessary)

**U.S. PATENT DOCUMENTS** 

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
CMW	2003171284	09/11/03	· Cox, et al.	514	12	
	2003191056	10/09/03	Walker, et al.	514	12	
	2003195154	10/16/03	Walker, et al.	514	12	
<u> </u>	6,602,498	08/05/03	Xiaoming Shen	424	78.08	<del> </del>
					ļ	
						•
					<del>                                     </del>	

**FOREIGN PATENT DOCUMENTS** 

		Document	Date	Country	Class	Subclass	Transl	
		Number					Yes	No
CMW		WO99/03887	01/28/99	PCT				
		WO2002/077218	10/03/02	PCT				
	<u> </u>	WO2001/003737	01/18/01	PCT				
	,	WO2001/62827	08/30/01	PCT				
	<u> </u>	WO2000/042175	07/20/00	PCT				
		WO2001/087925	11/22/01	РСТ				
	<u> </u>	EP0712931	05/22/96	· EPO	,			
	<u>.</u>	EP0692536	01/17/96	EPO				
	<u>.</u>	EP0974600	09/19/01	EPO	Ç			_
	<u> </u>	EP0819757	01/21/98	EPO				
		EP0816499	01/07/98	EPO .				
	<u> </u>	EP0845530	06/03/98	EPO				
		EP0859052	08/19/98	EPO				
	·	EP0821005	01/28/98	EPO				
		EP0767178	04/09/97	EPO	,			
L W		. EP110969A1	06/27/01	EPO				

Sheet 2 of 3.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office		SERIAL NO. 10/823,964	
	DISCLOSURE STATEMENT APPLICANT	APPLICANT Barn, et al.		
(Use severa	nl sheets if necessary)	FILING DATE 14 April 2004	GROUP Unknown	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
CMW	Pomroy, et al., "Solubilization of Hydrophobic Peptides by Reversible Cysteine PEGylation,"				
	Biochemical and Biophycial Research Communications, 245: 618-621 (1998).				
	Albrecht, et al., "Production of Soluble ScFVS with C-Terminal-Free Thiol for Site-Specific				
	Conjugation or Stable Dimeric ScFvs on Demand," Bioconjugate Chem., 15: 16-26 (2004).				
	Sato, et al., "Transglutaminase-Mediated Dual and Site-Specific Incorporation of Poly(ethylene				
1	glycol) Derivatives into a Chimeric Interleukin-2," Bioconjugate Chem., 11: 502-509 (2000).				
	Manjula, et al, "Site-Specific PEGylation of Hemogobin at Cys-93(β): Correlation between the				
	Colligative Properties of the PEGylated Protein and the Length of the Conjugated PEG Chain,"				
	Bioconjugate Chem., 14: 464-472 (2003).				
	Pettit, et al., "Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis,				
	Polyethylene Glycol Conjugation, and Homology Modeling," The Journal of Biological Chemistry,				
	<u>272 (4)</u> : 2312-2318 (1997).				
	Yang, et al., "Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins				
	by site-specific PEGylation," Protein Engineering, 16(10): 761-770 (2003).				
	Uchio, et al., "Site-specific insulin conjugates with enhanced stability and extended action profile,"				
	Advanced Drug Delivery Reviews, 35: 289-306 (1999).				
	Stimmel, et al., "Site-specific Conjugation on Serine-Cysteine Variant Monoclonal Antibodies," The				
	Journal of Biological Chemistry, 275 (39): 30445-30450 (2000).				
	Lee, et al., "Prolonged Circulating Lives of Single-Chain Fv Proteins Conjugated with Polyethylene				
į	Glycol: A Comparison of Conjugation Chemistries and Compounds," Bioconjugate Chem., 10: 973-				
	981 (1999).				
	Cantin, et al., "Polyethylene Glycol Conjugation at Cys <sup>232</sup> Prolongs the Half-Life of α1 Proteinase				
	Inhibitor," American Journal of Respiratory Cell Molecular Biology, 27: 659-665 (2002).				
	Andrew P. Chapman, "PEGylated antibodies and antibody fragments for improved therapy: a review				
	Advanced Drug Delivery Reviews, 54: 531-545 (2002).				
	Yoshioka, et al., "Optimal site-specific PEGylation of mutant RNF-α improves its antitumor				
	potency," Biochemical and Biophysical Research Communications, 315: 808-814 (2004).				
	Lee, et al., "N-Terminal Site-Specific Mono-PEGylation of Epidermal Growth Factor,"				
	Pharmaceutical Research, 20 (5): 818-825 (2003).				
	Clark, et al., "Long-acting Growth Hormones Produced by Conjugation with Polyethylene Glycol,"				
	The Journal of Biological Chemistry, 271 (36): 21969-21977 (1996).				
1//	Haruya Sato, "Enzymatic procedure for site-specific pegylation of proteins," Advanced Drug Deliver				
<b>V</b>	Reviews, 54: 487-504 (2002).				

Sheet 3 of 3.

Form PTO-1449	U.S. Department of Commerce		SERIAL NO.
	Patent and Trademark Office	PU60053	10/823,964
INFORMATIC	ON DISCLOSURE STATEMENT	APPLICANT	
BY APPLICANT		Bam, et al.	
(Use sev	eral sheets if necessary)	FILING DATE 14 April 2004	GROUP Unknown
		•	

OTHER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.)

CMW	Hinds, et al., "Effects of PEG conjugation 54: 505-530 (2002).	on insulin properties," Advanced Drug Delivery Reviews,
		Properties of a Humanized Anti-Interleukin-8 Antibody for fic Pegylation," Cytokine, 16 (3): 106-119 (2001).
	Seely, et al., "Issues encountered in the pro-	oduction of site-specific mono-PEGylated therapeutic
	proteins," Polymer Preprints (American Cl. 572-573 (1997).	hemical Society, Division of Polymer Chemistry), 38(1):
$ \downarrow $	conjugates," Peptides: The Wave of the Fu	hiolytic regeneration of active protein from its polymer ture, Proceedings of the Second International and the , San Diego, CA, June 9-14, 2001, pp. 953-954.
EXAMINER		DATE CONSIDERED
	/Cherie Woodward/	10/03/2006

•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.